Circulating Tumor Cells as a Screening and Diagnostic Marker for Early-Stage Non-Small Cell Lung Cancer

• Main Authors: Duan GC, Zhang XP, Wang HE, Wang ZK, Zhang H, Yu L, Xue WF, Xin ZF, Hu ZH, Zhao QT
• Format: Article
• Language: English
• Published: Dove Medical Press 2020-03-01
• Series: OncoTargets and Therapy
• Subjects: cellcollector; in vivo; circulating tumor cells; early-stage diagnosis; lung cancer
• Online Access: https://www.dovepress.com/circulating-tumor-cells-as-a-screening-and-diagnostic-marker-for-early-peer-reviewed-article-OTT

Guo-Chen Duan, Xiao-Peng Zhang, Hui-En Wang, Zhi-Kang Wang, Hua Zhang, Lei Yu, Wen-Fei Xue, Zhi-Fei Xin, Zhong-Hui Hu, Qing-Tao Zhao Department of Thoracic Surgery, Hebei General Hospital, Shijiazhuang, Hebei, People’s Republic of ChinaCorrespondence: Qing-Tao ZhaoDepartment of Thoracic Surgery, Hebei General Hospital, 348, West He-Ping Road, Shijiazhuang 050051, Hebei Province, People’s Republic of ChinaTel [phone]Email [e-mail]: Circulating tumor cells (CTCs) have become potential diagnostic biomarker for several types of cancer, including lung cancer. In this study, we aim to determine whether CTCs detected by CellCollector can be used for early-stage diagnosis of lung cancer.Methods: In this study, we recruited 64 volunteers, among whom 44 were suspected lung cancer patients requiring surgical treatment and 20 were healthy volunteers. We simultaneously analyzed PD-L1 expression in CTCs isolated using the GILUPI CellCollector and copy number variation by next-generation sequencing (NGS).Results: We enrolled a total of 44 patients with suspected lung cancer who required surgery and 20 healthy volunteers. The patients were classified into 4 groups based on their pathological results: benign disease, in situ cancer, microinvasive, and invasive. The CTCs detection rate for each group was 10.00% (1/10), 45% (5/11), 50% (7/14), and 67% (6/9), respectively. Among the patients with lung cancer, the CTCs detection rate increased with disease progression. The rate of CTCs positivity was 52.94% (18/34) in patients who were diagnosed with lung cancer by pathology and 10% (1/10) in patients with benign disease. CTCs were not detected in the control group. The area under the receiver operating characteristic (ROC) curve, a measure for distinguishing patients with primary lung cancer, was 0.715 (95% CI 0.549– 0.880, P=0.041). The sensitivity and specificity of the in vivo CTCs detection strategy for the diagnosis of early-stage lung cancer were 52.94% and 90%, respectively. CTCs were associated with clinical pathology but not with the size and location of the nodules.Conclusion: CTCs isolation using the CellCollector in vivo detection method might be effective for distinguishing between benign and malignant nodules and may be used for early-stage diagnosis of lung cancer.Keywords: CellCollector, in vivo, circulating tumor cells, early-stage diagnosis, lung cancer